Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginsenoside compound k (人参皂苷C-K) is a rare protopanaxadiol-type saponin metabolite derived from the intestinal microbial transformation of major ginsenosides found in Panax ginseng. It does not naturally occur in raw ginseng but is produced in the human gut after ingestion of other diol-type saponins such as Rb1 and Rd. Ginsenoside compound k exhibits multiple pharmacological activities including anti-tumor, anti-inflammatory, immunomodulatory, hepatoprotective, neuroprotective, and anti-aging effects. Mechanistically, it inhibits inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), modulates TGF-beta/Smad signaling pathways, suppresses memory T cell proliferation (notably CD4+ and CD8+), enhances collagen expression for skin protection against UV damage, and shows potential to enhance efficacy or reduce toxicity of standard chemotherapeutics. It has good water solubility compared to other related compounds like Rg3 or Rh2[2][3][4]. Clinical studies have explored its use for cancer therapy and rheumatoid arthritis[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginsenoside compound k.